Cortagen: research
A four-amino-acid brain peptide backed mainly by animal work and unverified patent claims.
Also called: Kortagen, AEDP, Ala-Glu-Asp-Pro.
Khavinson bioregulator peptides · Synthetic brain-cortex tetrapeptide.
Two patent examples report 27 exposed patients. No peer-reviewed clinical trial located; human donor-cell experiments are not clinical studies.
Studies
- Patent only: remote head injury. case-series, n=35, 35 people with head-injury effects persisting 1-10 years.. The patent reports better attention after microgram injections, without blinded assessment. (source)
- Patent only: vascular dementia. case-series, n=12, 12 people aged 69-76 with vascular dementia.. The patent claims symptom improvement; its percentage does not translate into a clear patient count. (source)
- Rat sciatic-nerve repair. animal, Rats after sciatic-nerve transection and suturing.. Cortagen increased nerve-fiber growth rate by 27% and conduction speed by 40%. (source)
- Delayed nerve recovery in rats. animal, Male Wistar rats after sciatic-nerve injury.. A follow-up examined nerve function months after injury; the PubMed record has no abstract. (source)
- Chronic brain ischemia in rats. animal, Rats with high or low tolerance to hypoxia.. Cortexin and Cortagen improved behavioral and oxidation measures in rats. (source)
- Ischemic preconditioning in rats. animal, Rats with chronic brain ischemia.. Peptide preparations reduced neurological deficits in this animal model. (source)
- Oxidation markers in rats. animal, Rat serum and cerebral cortex.. Cortagen and Epithalon reduced lipid and protein oxidation markers. (source)
- Negative comparison in chickens. animal, Hypophysectomized chickens and older birds.. Cortagen did not change the measured immunity and clotting outcomes; Epithalon did. (source)
- Immune signals from macrophages. in-vitro, Young and old mouse macrophage cultures.. Peptides including Cortagen altered lymphocyte-activating signals in a context-dependent way. (source)
- Hypothalamic IL-2 expression. animal, Rat hypothalamus after short-peptide injections.. Peptides changed IL-2 gene expression depending on route and timing. (source)
- Gene expression in mouse hearts. animal, Six-month-old female CBA mice.. Cortagen changed expression of 234 of 15,247 measured clones, matching 110 known genes. (source)
- Chromatin in older donors' cells. in-vitro, Cultured leukocytes from donors aged 75-88.. Short peptides including Cortagen changed chromatin and ribosomal-gene activity. (source)
- Chromatin study in donor cells. in-vitro, Lymphocyte cultures from people aged 75-88 and 20-40.. Peptides changed chromatin packing; no participant received Cortagen. (source)
- Older chromatin in cell culture. in-vitro, Lymphocyte cultures from older donors.. Cortagen was among peptides with selective effects on chromosome regions. (source)
- IL-2 in mouse spleen cells. in-vitro, Mouse splenocytes in culture.. Cortagen increased IL-2 mRNA less strongly than Vilon or Epithalon. (source)
- Negative thymocyte finding. in-vitro, Mouse thymocyte cultures and membranes.. Cortagen had no comitogenic effect in the tested proliferation assay. (source)
- Rat tissue cultures across ages. in-vitro, Organ cultures of rat brain, liver and thymus.. Cortagen was one of several peptides with tissue-specific explant effects. (source)
- Tissue-specific explant growth. in-vitro, Rat brain and other organ explants.. Cortagen stimulated brain-cortex explant growth under laboratory conditions. (source)
- Electrical effects in isolated neurons. in-vitro, Isolated pond-snail neurons.. Low and high concentrations had different electrical effects; high concentrations inhibited ion currents. (source)
Cortagen dosage
Typical reported dose: 50 mcg per nasal spray, used daily
- Fifty micrograms per nasal spray: 50 mcg per spray; daily spray count not established. daily use reported; sprays per day unclear, nasal spray. Reported by users, rare report. Studied in: Adults in online discussions; frequency in the wider community is unknown. (source)
- Forum claim: 5-10 mg alternate days: 5-10 mg every other day. every other day, into muscle. Reported by users, rare report. Studied in: Adults in online discussions; frequency in the wider community is unknown. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Cortagen side effects and risks
Reported side effects
- Allergic or injection-related reactions: No compound specific rate is established. These are general risks of unapproved peptide products., serious. Stop use and seek care for a spreading reaction or signs of infection. (source)
- Other short- and long-term effects: No reliable adverse event denominator is available., moderate. Report new symptoms and the exact product, dose, route and timing. (source)
- Scalp tingling: One online user reported tingling; causation and frequency are unknown., mild. New painful zaps, weakness or seizure-like symptoms need clinical assessment. (source)
Stop and get help if
- Trouble breathing, throat swelling, widespread hives or collapse: Call emergency services now; these may be signs of anaphylaxis.
- Fever with confusion, rapid breathing or a very painful spreading injection-site infection: Get emergency care now; severe infection can progress quickly.
- Sudden face droop, one-sided weakness, speech trouble or vision loss: Call emergency services now, even if symptoms improve. These can be stroke signs.
- Chest pressure or pain with shortness of breath, sweating or lightheadedness: Call emergency services now for possible heart attack.
- A seizure lasting over 5 minutes, repeated seizures or trouble breathing afterward: Call emergency services now.
Who should avoid it
- pregnant: Precaution: no reliable pregnancy safety data for this peptide.
- breastfeeding: Precaution: transfer into milk and infant effects are unknown.
- tryingToConceive: Precaution: fertility and early-pregnancy effects are unknown.
- under18: Precaution: no reliable pediatric safety evidence was located.
- kidneyDisease: Clearance and dose adjustment in kidney disease are unknown.
- liverDisease: No liver-disease dose or safety study was located.
- testedAthlete: The 2026 S0 rule is expected to prohibit this unapproved substance at all times.
- seizureDisorder: Precaution: isolated neurons showed electrical effects. Safety in people with seizures has not been established.
- activeCancer: Cancer safety is unknown. Gene-expression and explant-growth experiments do not establish safety in tumors.
- autoimmuneDisease: Immune-cell signaling changes were seen in vitro; clinical effects in autoimmune disease are unknown.
Interactions
- Other brain-directed peptides or peptide mixtures: Co-use is reported, but interaction safety and added benefit have not been established. Cortexin is a different preparation.
- Antiseizure medicines: No human interaction study was located. Nerve-cell electrical effects do not show that it can replace seizure medicines.
Product quality risks
- No independent published market-testing study specific to this peptide was located.
- General peptide warnings describe wrong strength, wrong ingredients and microbial contamination.
- An online semaglutide study found low purity and endotoxin. This does not measure contamination in this peptide.
How Cortagen works
Laboratory studies suggest effects on nerve growth, gene activity and electrical signaling in nerve cells. Findings depend on the model and concentration. None establishes how Cortagen works in a person or whether it reaches the brain at useful levels.
- Gene expression and chromatin: Mouse-heart and donor-cell experiments found changes in gene activity and DNA packing.
- Nerve-cell ion currents: Isolated mollusk neurons showed concentration-dependent electrical effects, including inhibition at high concentrations.
Half-life: Unknown in humans.
Gaps: No peer-reviewed human clinical trial, registered Cortagen study or reliable human pharmacokinetic study was located. Patent human doses were 1 and 3 mcg IM daily; they are not approved or peer-reviewed dosing protocols. Community IM alternate-day amounts cannot be compared with daily patent amounts as a studied maximum. No human subcutaneous, intranasal or sublingual studied maximum is known. Clinical-benefit claims for Cortexin, Epitalon or other bioregulators cannot be assigned to Cortagen. Reliable adverse-event rates, reproductive safety, long-term cancer safety and drug-interaction data are missing. Community dosing prevalence is unknown; many pages repeat templates instead of documenting use. No independent market-testing study or validated reconstitution and storage method specific to Cortagen was found.
Related to Cortagen
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Pinealon: A peptide with unproven brain benefits and no established injection dose.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Thymogen: A Russian peptide used for immune problems, with negative cancer trials.
- Vesugen: An experimental blood-vessel peptide with unclear benefits and poorly defined safety.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, US Food and Drug Administration · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, National Library of Medicine
- Drugs@FDA: FDA-Approved Drugs, US Food and Drug Administration
- First Aid for Seizures, Centers for Disease Control and Prevention
- Heart Attack, National Library of Medicine
- Sepsis, National Library of Medicine
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.